|
 |
|
|
| |
News - May, 2008
The Rocky Mountain Blood and
Marrow Transplant Program is committed to ongoing
education in the field. We are providing the latest
treatment and research news around our program for
patients and their caregivers and physicians.
|
05-16-2008 |
New drug combination brings 1-2 punch against acute leukemia
Researchers at The University of Texas M. D. Anderson Cancer Center have discovered a drug combination that kills leukemia cells by shutting down their energy source and hastening cell starvation.
|
|
05-14-2008 |
Mile High Amazing Race Downtown Denver 5/17 (external link)
Get ready for the most AMAZING RACE for Life! Many have seen the television show; now here's a chance to race in your own adventure! The 2nd Annual Mile High Amazing race to Benefit The Leukemia, Lymphoma's Society is a one-day event that will be on Saturday, May 17, 2007 in Downtown Denver.
|
|
05-12-2008 |
Arsenic-based therapy shown to help eradicate leukemia-initiating cells
In both leukemia and solid tumors, there exists among the multitude of warrior cancer cells a small subgroup that work undercover, patiently lying in wait to launch their attacks. Known as either cancer initiating cells (CICs) or leukemia initiating cells (LICs), these stealth populations are impervious to conventional chemotherapy and undaunted by targeted cancer therapies. When a leukemia patient relapses following a period of remission, it is the LICs that bear responsibility for the disease's reemergence.
|
|
05-12-2008 |
Stem Cell Transplant Procedures Vary Throughout the World (external link)
Stem cell transplant practices vary substantially among physicians treating adults and children with hematologic malignancies (cancers of the blood or bone marrow such as leukemias and lymphomas). These findings were published in the Journal of Clinical Oncology.
|
|
05-09-2008 |
Lenalidomide raises clot risk in multiple myeloma patients (external link)
Thromboembolic events are increased in patients undergoing lenalidomide-based therapy for multiple myeloma, US and Italian researchers report. Aspirin prophylaxis appears to reduce this risk.
|
|
05-08-2008 |
Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine (VNP40101M) in Combination with Cytarabine
Vion Pharmaceuticals, Inc. today announced the start of an investigator-sponsored Phase I/II clinical trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in elderly patients with previously untreated acute myelogenous leukemia (AML) and high-risk myelodysplastic syndromes (MDS). The trial is being conducted under the direction of Ellen K. Ritchie, M.D. at The Weill-Cornell Medical College in New York City. Co- investigators for the study are Eric Feldman, M.D. and Gail Roboz, M.D.
|
|
|
|
|
|
|
